New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT07395258
First seen Feb 13, 2026 · Last updated Jun 11, 2026 · Updated 20 times
Summary
This early-phase study tests a new experimental drug (BI 3923948) in 60 adults with advanced solid tumors that have spread and are not responding to standard treatments. The drug is injected directly into tumors, either alone or combined with an immune-boosting antibody (checkpoint inhibitor). The main goal is to find a safe dose and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.